Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth
This report analyzes biopharmaceutical manufacturing and the contract manufacturing industry in India, China, and South Korea. It provides an overview of regulatory frameworks, infrastructure support, and funding that have created an environment conducive to industry growth. The report details market sizes and forecasts through 2016, as well as trends such as outsourcing and partnerships between pharmaceutical companies and contract manufacturers in these regions. It also profiles major players and assesses factors like operating costs, skills, and government initiatives that affect industry competitiveness in each country.
As one of the most important methods to increase production in current global agricultural development, pesticide market presents stable growth in recent years. In 2006-2012, chemical pesticide API (converting into active ingredient) output of China attained CAGR of 18.3%, but declined by 10% in 2013 greatly influenced by backward capacity elimination under stringent environmental protection requirement of pesticide industry. However, the price increase offset the unfavorable impact brought by output dropping, operating revenue of Chinese pesticide industry surged by 19.3% year-on-year to RMB281.3 billion, and total profit reached RMB22.93 billion, presenting a 30.9% YoY rise in 2013.
China is not only the big pesticide producer and consumer, but also the large exporter. In 2013, the pesticide export volume soared up by 22.1% yr-on-yr to 1,095kt, and the export structure experienced significant change. Also in the same year, pesticide preparation exported shared about 60% of total export, being the major variety of pesticide export. In addition, the export volume of herbicide, bactericide and insecticide occupied 68%, 23% and 8% of the total, respectively.
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
Pharmaceutical, Bulk Drugs and Medicine Manufacturing Industry (Production, F...Ajjay Kumar Gupta
Quality control and quality assurance are vital in this industry. Many production workers are assigned full time to quality control and quality assurance functions, whereas other employees may devote part of their time to these functions. For example, although pharmaceutical company sales representatives, often called detailers, work primarily in marketing, they engage in quality control when they assist pharmacists in checking for outdated products.
Advances in manufacturing processes are also impacting the industry. While pharmaceutical manufacturers have long devoted resources to new drug development as a source for future profits, firms are increasingly realizing that improvements throughout the drug pipeline are needed to stay competitive.
See more
http://goo.gl/1sQLwS
http://goo.gl/jajeNa
http://goo.gl/0tvlst
http://www.entrepreneurindia.co/
Tags
Pharmaceutical Technology Books, Essentials of Pharmaceutical Technology, Pharmaceutical Technology, Pharmaceutical books, Science, Technology & Medicine Books, Drugs technology books, Drug and Pharmaceuticals technology book, Best small and cottage scale industries, Bulk Drugs Formulation, Bulk Drugs Manufacturing Industry, Business consultancy, Business consultant, Business guidance for Pharmaceutical industry, Business guidance to clients, Business Plan for a Startup Business, Creating a Pharma Start-up, Drug formulation manual, Formulation of Antibiotics, Formulation of Paracetamol, Formulation of Tablets, Great Opportunity for Startup, How to Start a Medicines manufacturing business?, How to start a pharmaceutical company, How to Start a Pharmaceutical Product Business, How to Start a Pharmaceutical Production Business, How to start a pharmacy business, How to start a successful drugs making business, How to start Antibiotics manufacturing business, How to start drugs pharmaceutical business, How to start medicine business, How to Start Medicine Manufacturing Industry in India, How to start medicine manufacturing, How to start Paracetamol production business, How to Start Pharmaceutical Manufacturing Company in India, Invest to setup a pharmaceutical business, Manufacturing of medicinal products- Pharmaceutical industry, Medicine Manufacturing Industry, Medicines Making Small Business Manufacturing, Modern small and cottage scale industries, Most Profitable Bulk Drugs production Business Ideas, New small scale ideas in Pharmaceutical industry, Pharma Manufacturing, Pharmaceutical and Medicines production Business, Pharmaceutical Based Profitable Projects, Pharmaceutical Based Small Scale Industries Projects, Pharmaceutical Drug Formulation, Pharmaceutical Drug Manufacturing Business, Pharmaceutical formulation guidelines, Pharmaceutical formulation, Pharmaceutical industry in India, Pharmaceutical industry, Pharmaceutical manufacturing Industry in India, Pharmaceutical Manufacturing Industry, Pharmaceutical Projects,
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
As one of the most important methods to increase production in current global agricultural development, pesticide market presents stable growth in recent years. In 2006-2012, chemical pesticide API (converting into active ingredient) output of China attained CAGR of 18.3%, but declined by 10% in 2013 greatly influenced by backward capacity elimination under stringent environmental protection requirement of pesticide industry. However, the price increase offset the unfavorable impact brought by output dropping, operating revenue of Chinese pesticide industry surged by 19.3% year-on-year to RMB281.3 billion, and total profit reached RMB22.93 billion, presenting a 30.9% YoY rise in 2013.
China is not only the big pesticide producer and consumer, but also the large exporter. In 2013, the pesticide export volume soared up by 22.1% yr-on-yr to 1,095kt, and the export structure experienced significant change. Also in the same year, pesticide preparation exported shared about 60% of total export, being the major variety of pesticide export. In addition, the export volume of herbicide, bactericide and insecticide occupied 68%, 23% and 8% of the total, respectively.
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
Pharmaceutical, Bulk Drugs and Medicine Manufacturing Industry (Production, F...Ajjay Kumar Gupta
Quality control and quality assurance are vital in this industry. Many production workers are assigned full time to quality control and quality assurance functions, whereas other employees may devote part of their time to these functions. For example, although pharmaceutical company sales representatives, often called detailers, work primarily in marketing, they engage in quality control when they assist pharmacists in checking for outdated products.
Advances in manufacturing processes are also impacting the industry. While pharmaceutical manufacturers have long devoted resources to new drug development as a source for future profits, firms are increasingly realizing that improvements throughout the drug pipeline are needed to stay competitive.
See more
http://goo.gl/1sQLwS
http://goo.gl/jajeNa
http://goo.gl/0tvlst
http://www.entrepreneurindia.co/
Tags
Pharmaceutical Technology Books, Essentials of Pharmaceutical Technology, Pharmaceutical Technology, Pharmaceutical books, Science, Technology & Medicine Books, Drugs technology books, Drug and Pharmaceuticals technology book, Best small and cottage scale industries, Bulk Drugs Formulation, Bulk Drugs Manufacturing Industry, Business consultancy, Business consultant, Business guidance for Pharmaceutical industry, Business guidance to clients, Business Plan for a Startup Business, Creating a Pharma Start-up, Drug formulation manual, Formulation of Antibiotics, Formulation of Paracetamol, Formulation of Tablets, Great Opportunity for Startup, How to Start a Medicines manufacturing business?, How to start a pharmaceutical company, How to Start a Pharmaceutical Product Business, How to Start a Pharmaceutical Production Business, How to start a pharmacy business, How to start a successful drugs making business, How to start Antibiotics manufacturing business, How to start drugs pharmaceutical business, How to start medicine business, How to Start Medicine Manufacturing Industry in India, How to start medicine manufacturing, How to start Paracetamol production business, How to Start Pharmaceutical Manufacturing Company in India, Invest to setup a pharmaceutical business, Manufacturing of medicinal products- Pharmaceutical industry, Medicine Manufacturing Industry, Medicines Making Small Business Manufacturing, Modern small and cottage scale industries, Most Profitable Bulk Drugs production Business Ideas, New small scale ideas in Pharmaceutical industry, Pharma Manufacturing, Pharmaceutical and Medicines production Business, Pharmaceutical Based Profitable Projects, Pharmaceutical Based Small Scale Industries Projects, Pharmaceutical Drug Formulation, Pharmaceutical Drug Manufacturing Business, Pharmaceutical formulation guidelines, Pharmaceutical formulation, Pharmaceutical industry in India, Pharmaceutical industry, Pharmaceutical manufacturing Industry in India, Pharmaceutical Manufacturing Industry, Pharmaceutical Projects,
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Contract manufacturing organizations are in a strategic position to serve as the trusted and experienced providers of the industry's most advanced equipment and manufacturing processes.
Rising costs and increasingly complex technologies have put demand for CMOs at an all-time high. Read on to learn about the factors affecting the CMO market and how to select the CMO that's right for you.
https://www.icqconsultants.com/white_paper/biopharma-contract-manufacturing/
"Description:
Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?
Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?
What is covered in this report?
- Overview of China’s red biotechnology;
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations
What benefits will you get?
- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;
- Keep informed of the precise development situation of key RB products with basic data and latest info;
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;
- Figure out, current trend and future growth prospect of red biotechnology in China;
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.
"
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".Rosmirella Cano Rojas
Pharmacovigilance (PV) is under unprecedented stress from fundamental changes in a booming pharmaceutical industry, from the challenges of creating and maintaining an increasingly complex PV system in a globally diverse regulatory environment, and from unpredicted consequences of historical PV cost-reduction strategies. At the same time, talent availability lags demand, and many PV professionals may no longer be finding personal fulfillment in their careers.
The situation creates risks for companies. Advantages and disadvantages of potential strategies to address this increasing problem at a corporate and industry level and in collaboration with regulatory agencies are discussed, as well as opportunities to adopt new technologies, including artificial intelligence and machine- learning to automate pharmacovigilance operations.
These approaches would address burdensome and wasteful effort assuring regulatory compliance and free up resources to support the original mission of PV as an important public health activity and to reinvest in the development of new drugs.
Pharmaceutical Industry Financial Analysisjpotts89
This is a presentation that was completed for my Corporate Finance class my senior year with a team of three other students. I did my valuation of Eli Lilly.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
The report contains the following four chapters:
Chapter 1: Global Pharmaceutical Market
Chapter 2: Solutions to Challenges
Chapter 3: Global Players
Chapter 4: Overview of Industry Trends
You may follow my blog: biostrategyanalytics.wordpress.com for further posts related to financial and strategic issues in the Pharmaceutical / Biotechnology sector.
For any questions or recommendations do not hesitate to contact me.
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Contract manufacturing organizations are in a strategic position to serve as the trusted and experienced providers of the industry's most advanced equipment and manufacturing processes.
Rising costs and increasingly complex technologies have put demand for CMOs at an all-time high. Read on to learn about the factors affecting the CMO market and how to select the CMO that's right for you.
https://www.icqconsultants.com/white_paper/biopharma-contract-manufacturing/
"Description:
Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?
Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?
What is covered in this report?
- Overview of China’s red biotechnology;
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations
What benefits will you get?
- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;
- Keep informed of the precise development situation of key RB products with basic data and latest info;
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;
- Figure out, current trend and future growth prospect of red biotechnology in China;
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.
"
"Pharmacovigilance in Crisis: Drug Safety at a Crossroads, 2018".Rosmirella Cano Rojas
Pharmacovigilance (PV) is under unprecedented stress from fundamental changes in a booming pharmaceutical industry, from the challenges of creating and maintaining an increasingly complex PV system in a globally diverse regulatory environment, and from unpredicted consequences of historical PV cost-reduction strategies. At the same time, talent availability lags demand, and many PV professionals may no longer be finding personal fulfillment in their careers.
The situation creates risks for companies. Advantages and disadvantages of potential strategies to address this increasing problem at a corporate and industry level and in collaboration with regulatory agencies are discussed, as well as opportunities to adopt new technologies, including artificial intelligence and machine- learning to automate pharmacovigilance operations.
These approaches would address burdensome and wasteful effort assuring regulatory compliance and free up resources to support the original mission of PV as an important public health activity and to reinvest in the development of new drugs.
Pharmaceutical Industry Financial Analysisjpotts89
This is a presentation that was completed for my Corporate Finance class my senior year with a team of three other students. I did my valuation of Eli Lilly.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
The report contains the following four chapters:
Chapter 1: Global Pharmaceutical Market
Chapter 2: Solutions to Challenges
Chapter 3: Global Players
Chapter 4: Overview of Industry Trends
You may follow my blog: biostrategyanalytics.wordpress.com for further posts related to financial and strategic issues in the Pharmaceutical / Biotechnology sector.
For any questions or recommendations do not hesitate to contact me.
Pittsburgh Nonprofit Summit - Managing and Supporting a Changing Labor MarketGPNP
As the nonprofit sector prepares for significant leadership transition, as the next generation is looking for a different work experience, and as the average tenure of employees continues to decrease, what will be the impact on nonprofits as they prepare for the changing labor market? Here, Stefani Pashman from the Three Rivers Workforce Investment Board shares a look at the Pittsburgh nonprofit labor market.
Medienhandeln von bildungsbenachteiligten Jugendlichen als BildungsressourceNiels Brüggen
Vortrag am 02.12.2009 auf der Fachtagung "Klicken und Glotzen" über das Medienhandeln von Jugendlichen, die in benachteiligten Verhältnissen aufwachsen
Dr Anselm Goerres - Marktwirtschaftlichen umweltpolitik: Wer sind wir überhau...noe21
http://www.managing-energy-demand.org
This seminar held on november 4 ‘09 in Bern, Switzerland, hosted international specialists in managing energy demand, mainly electric energy. Presentations concentrated on best cases in demand side management and regulation easing the way for DSM programs. The event was organised by noe21, a Geneva based NGO.
TRABAJO EN EQUIPO: EL PODER TRABAJAR CON UN GRUPO SEA LABORAL, ESCOLAR ETC., TRAERÁ GRANDES APORTACIONES Y LOGROS SIMILARES , PRINCIPIOS IMPORTANTES QUE DEBE TENER UN EQUIPO.
Similar to Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth
Biotechnology Reagents Market PPT: Growth, Outlook, Demand, Keyplayer Analysi...IMARC Group
The global biotechnology reagents market size reached US$ 78,719 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 126,677 Million by 2028, exhibiting a growth rate (CAGR) of 8.50% during 2023-2028.
More Info:- https://www.imarcgroup.com/biotechnology-reagents-market
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”
Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 b...Ajjay Kumar Gupta
Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023: Investment Opportunity for Startups and Entrepreneurs, Medications, Drugs and Pharmaceuticals, Cephalexin Monohydrate, Ampicilin Trihydrate, Ibuprofen Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule, Working Capital Requirement, Plant Layout, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis
Production of active pharmaceutical ingredients is a highly sophisticated and technically demanding process. The global active pharmaceutical ingredient market is surging due to the increased demand for pharmaceutical drugs, which in turn is driven by aging population, increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular, neurological and infectious diseases among others. The global Active Pharmaceutical Ingredient market for was valued at US$ 12.9 bn in 2014 and is estimated to reach US$ 21.9 billion by 2023 at a CAGR of 6.3% from 2015 to 2023.
See more
https://goo.gl/dwgi0H
https://goo.gl/qRJmnp
https://goo.gl/t2QFiI
Contact us:
Niir Project Consultancy Services
106-E, Kamla Nagar, Opp. Spark Mall,
New Delhi-110007, India.
Email: npcs.ei@gmail.com , info@entrepreneurindia.co
Tel: +91-11-23843955, 23845654, 23845886, 8800733955
Mobile: +91-9811043595
Website :
http://www.niir.org
http://www.entrepreneurindia.co
Tags
Active Pharmaceutical Ingredients Manufacturing, Active Pharmaceutical Ingredients, API Manufacture in India, API Manufacturing, Manufacturing of Active Pharmaceutical Ingredients, API Manufacturing Industry, API Manufacturing Plant, Active Pharmaceutical Ingredient Manufacture, Manufacture of Active Pharmaceutical Ingredients, Manufacturing of Active Pharmaceutical Ingredients, Active Pharmaceutical Ingredient Manufacturing Plant, Processing of Active Pharmaceutical Ingredient, Active Pharmaceutical Ingredients Plant, Preparation of Active Pharmaceutical Ingredients (API), Active Pharmaceutical Ingredients Industry, Production of Active Pharmaceutical Ingredients (API), Active Pharmaceutical Ingredients Manufacturing Unit, Plans to Set Up API (Active Pharmaceutical Ingredients) Manufacturing Project, Active Pharmaceutical Ingredient Manufacturing Process, Active Pharmaceutical Ingredients Production, Production Process of API, Active Pharmaceutical Ingredient (API) Production, API Manufacturing Process, Business Planning for Active Pharmaceutical Ingredients Manufacturing, Business Plan for Manufacturing Active Pharmaceutical Ingredient, Start Active Pharmaceutical Ingredient (API) Production Business, Plant for Production of Active Pharmaceutical Ingredient
Biobanking Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opport...IMARC Group
The global biobanking market size reached US$ 57.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 82.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.86% during 2023-2028.
More Info:- https://www.imarcgroup.com/biobanking-market
The key advantage of bioinks lies in their unique composition, combining living cells with biomaterials that allows for the precise 3D printing of functional tissues.
Indian Vaccine Market by Product Type, Distribution Channel, End User 2024-2032IMARC Group
The Indian vaccine market size is expected to exhibit a growth rate (CAGR) of 12.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/indian-vaccine-market
Food Preservatives Market by Product Type, Distribution Channel, End User 202...IMARC Group
The global food preservatives market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032.
More Info:- https://www.imarcgroup.com/food-preservatives-market
Polyhydroxyalkanoate are linear polyesters that are produced from fermentation of lipid or sugar by bacteria. The rising demand for biodegradable materials, increase in oil prices and policies concerning green procurement are the driving factors for investment by companies in this market.
Detailed Project Report on Setting up a Blueberry Processing PlantIMARC Group
The report provides a complete roadmap for setting up an blueberry processing plant. It covers a comprehensive market overview to micro-level information such as unit operations involved, raw material requirements, utility requirements, infrastructure requirements, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, etc.
More Info:- https://www.imarcgroup.com/blueberry-processing-plant-project-report
Biobanking Market by Product Type, Distribution Channel, End User 2023-2028IMARC Group
The global biobanking market size reached US$ 57.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 82.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.86% during 2023-2028.
More Info:- https://www.imarcgroup.com/biobanking-market
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...IMARC Group
The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during 2022-2027.
More Info:- https://www.imarcgroup.com/companion-diagnostics-market
Similar to Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth (20)
Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth
1. Biopharmaceutical Manufacturing in India, China and South
Korea - Regulatory Framework, Infrastructure Support and
Discovery Funding Create an Environment Conducive to Growth
Report Details:
Published:October 2012
No. of Pages: 82
Price: Single User License – US$3500
GBI Research, the leading business intelligence provider has released its latest research report,
“Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework,
Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth”. The
report provides an analysis of biopharmaceuticals approved in 2010 and 2011, operating
dynamics in the biopharmaceutical industry, the current scenario in biopharmaceutical
manufacturing, key stakeholders, the current market size (2011) of biopharmaceuticals, and
forecasts to 2016 for India, China, South Korea and the global market. The report also presents
trends witnessed in biopharmaceutical manufacturing, preferred partnership pricing models,
contract manufacturing partnerships, comparative analysis of biopharmaceutical manufacturing in
India, China and South Korea, and the competitive landscape for the countries covered in the
report.
This report is built using data and information sourced from proprietary databases, primary and
secondary research, and in-house analysis from GBI Research’s team of industry experts.
Leading Contract Manufacturing Organizations (CMOs) offer manufacturing functions both
upstream and downstream equally. In addition to manufacturing in biopharmaceutical production,
they also offer clinical trials, logistics, packaging, and even marketing. According to industry
experts, almost 60% of the CMO market is dominated by manufacturing functions, out of which
more than 50% is dominated by the downstream process. Many pharmaceutical companies are
expected to outsource most parts of their R&D and biopharmaceutical manufacturing to emerging
economies such as India and China. Cost rationalization and skilled labor are the main factors
facilitating the outsourcing of processes to these countries. Contract manufacturing is experiencing
an upsurge in these countries; outsourcing activities for biopharmaceutical manufacturing include
secondary manufacturing such as fill and finish operations, mammalian cell culture, Active
Pharmaceutical Ingredient (API) biologics, microbial fermentation and plant cells. Outsourcing
analyses by pharmaceutical companies reveal that product characterization testing such as
biomanufacturing, toxicity, bioassays and analytical testing form the bulk of outsourcing to CMOs.
With the increase in outsourcing, biomanufacturing capacities in emerging economies have been
2. expanding. Although the US continues to be a leader in biopharmaceutical production, with
approximately 45% of the total production share, China’s and India’s shares have been
continuously increasing, with 8% and 7% respectively. Sponsors are building strategic
relationships with the contract players and progressively working towards homogenizing and
simplifying manufacturing processes in order to ensure normalized products.
Scope
•Detailed overview of biopharmaceutical manufacturing, the CMO industry, and recent approvals
of biopharmaceuticals.
•Annualized market data and forecasts to 2016 for the biopharmaceutical market in India, China
and South Korea.
•Detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers
and restraints of the market.
•Detailed discussion of trends witnessed in biopharmaceutical manufacturing.
•Company profiles of key biopharmaceutical players in India, China and South Korea, including
the key services they offer and the production capacity of the global top 10 biopharmaceutical
companies.
Reasons to buy
•Develop market entry and market expansion strategies by identifying areas for high growth and
opportunities.
•Understand the factors shaping the biopharmaceutical industry and trends witnessed in the
biopharmaceutical industry.
•Identify the top players in the biopharmaceutical industry, including their financial revenues,
geographical presence and key services offered.
•Analyze the key geographies that are lucrative markets for biopharmaceutical production and
CMOs.
•Understand upcoming trends that are poised to drive the future growth of biopharmaceutical
production.
Get your copy of this report @
http://www.reportsnreports.com/reports/195910-biopharmaceutical-manufacturing-in-india-china-and-south-korea-
regulatory-framework-infrastructure-support-and-discovery-funding-create-an-environment-conducive-to-
growth.html
Major points covered in Table of Contents of this report include
Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Biopharmaceutical Manufacturing in India, China and South Korea - Introduction 11
2.1 Introduction 11
3 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of the
Biopharmaceutical Industry 12
3.1 Definition and Objective Analysis of Newly Approved Biopharmaceuticals 12
3.2 Collective Analysis of Biopharmaceuticals Approved in 2010 and 2011 15
3. 3.3 Current Scenario in Biopharmaceutical Manufacturing 17
3.4 Biopharmaceutical Manufacturing 22
3.5 Factors Driving Outsourcing to India, China and South Korea 23
3.5.1 Comparative Cost Analysis between In-House Biopharmaceutical Production Versus
Contract Manufacturing Organizations 23
3.6 Growth Drivers for Contract Research and Manufacturing Services 24
3.7 Contract Manufacturing Benefits 26
3.8 Operating Cost Analysis in Biopharmaceutical Manufacturing 27
3.8.1 Labor Cost Analysis 27
3.8.2 Investment Cost Analysis 28
3.8.3 Standard Operating Costs 29
3.9 Cost and Timeline Analysis for Therapeutic Monoclonal Antibody Product Development 31
3.10 Manufacturing Equipment Trends 34
3.11 Comparative Analysis of New and Old Equipment 35
3.12 Consolidation in Pharmaceutical Industry has Resulted in Idle Production Lines 36
3.13 Biosimilars in Asia 38
3.14 CMOs to Benefit by Expanding Operations in Biopharmaceutical Manufacturing 38
3.15 Trends Witnessed in Biopharmaceutical Manufacturing 39
3.15.1 Single-Use Bioprocessing and Microbial Technologies to Dominate Biopharmaceutical
Manufacturing 39
3.15.2 Biopharmaceutical R&D and Manufacturing Outsourcing to Rise 39
3.15.3 Market for Biopharmaceuticals to Rise at Brisk Rate 39
3.15.4 Introduction of Biosimilars to Multiply Biopharmaceutical Manufacturers 39
3.15.5 R&D Spend in Biopharmaceuticals Insulated from Economic Downturn 40
3.15.6 Downstream Processing Technologies Acting as Bottleneck in Biopharmaceutical
Manufacturing 40
3.16 Preferred Biopharmaceutical Contract Pricing Model 40
3.17 Contract Manufacturing Partnerships 41
3.18 Comparative Analysis of India, China and South Korea with Reference to Government
Initiatives, Investment and Skills 43
4 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of
Biopharmaceutical Manufacturing in India 44
4.1 Augmentation Potential of Biopharmaceuticals in India 44
4.1.1 Stem Cells 44
4.1.2 Biosimilars 44
4.1.3 Vaccines 46
4.2 Biopharmaceutical Revenues in India 47
4.3 Drivers and Barriers for Biopharmaceutical Manufacturing in India 48
4.4 Proposals to the Government for Promoting Biopharmaceutical Manufacturing 49
4.5 Pharmaceutical Cluster Development in India 49
4.6 Regulatory Overview for Biopharmaceuticals in India 50
4.7 Competitive Landscape 51
4. 4.7.1 Biocon Ltd. 51
4.7.2 Serum Institute of India Ltd. 52
4.7.3 Panacea Biotec Ltd 53
4.7.4 Dr. Reddy’s 54
4.7.5 Cipla 55
4.7.6 Lupin 56
5 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of
Biopharmaceutical Manufacturing in China 57
5.1 Market Size for Chinese Biopharmaceuticals 57
5.2 Economic Impact of Biopharmaceuticals Approved in China 59
5.3 Biopharmaceuticals under Progression in China 61
5.3.1 Antibodies 61
5.3.2 Long-acting Proteins 61
5.3.3 Gene Therapy Products 61
5.3.4 New vaccines 61
5.4 Challenges Faced by Biopharmaceuticals in China 62
5.4.1 Overproduction of Simpler Drugs is Leading to Over-Competition in Domestic Markets 62
5.4.2 Weak Strategic Planning and Management Skills 62
5.4.3 Expression Deficit to Limit the Development and Industrialization of Biopharmaceuticals 62
5.5 Propositions for the Advancement of Biopharmaceuticals in China 62
5.5.1 Internationalize the Regulatory System to Eliminate Deficiencies for Biopharmaceutical
Products 62
5.5.2 Breakthrough Innovation is Critical for the Success of Biopharmaceuticals 62
5.5.3 Set up Industrial Standards and Fortify Manufacturing Capacity 62
5.5.4 Augment Communication Between Researchers and Clinicians for Developing
Biopharmaceuticals 63
5.6 Contract Manufacturing Scenario in China 63
5.7 Competitive Landscape 64
5.7.1 Hualan Biological Engineering Co., Ltd. 64
5.7.2 Shanghai Kehua Biological Engineering Co., Ltd. 65
5.7.3 Beijing Tiantan Biological Products Co., Ltd. 66
5.7.4 Beijing SL Pharmaceutical Co., Ltd. 67
5.7.5 Shanghai RAAS Blood Products Co., Ltd. 68
6 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of
Biopharmaceutical Manufacturing in South Korea 69
6.1 South Korean Biopharmaceutical Industry 69
6.2 Market Size for South Korean Biopharmaceuticals 70
6.3 Evolution of the Biopharmaceutical Industry in South Korea 71
6.4 Korean Free Trade Agreement with the US 71
6.5 Drivers Affecting Biopharmaceuticals in South Korea 72
6.5.1 Korea/US Free Trade Agreement 72
6.5.2 Punishment Systems and Price Reduction 72
5. 6.5.3 Government Initiatives for the Development of the Biopharmaceutical Industry 72
6.6 Major R&D Achievements in South Korea 72
6.7 South Korea’s Strategic Advantage over India and China 72
6.8 Competitive Landscape 73
6.8.1 Celltrion 73
6.8.2 LG Life Sciences 74
6.8.3 Hanwha Chemical 75
6.8.4 ISU Abxis 76
6.8.5 Green Cross 77
7 Biopharmaceutical Manufacturing in India, China and South Korea - Appendix 78
7.1 Market Definitions 78
7.2 Abbreviations 78
7.3 Bibliography 79
7.4 Research Methodology 80
7.4.1 Coverage 80
7.4.2 Secondary Research 81
7.4.3 Primary Research 81
7.4.4 Expert Panel Validation 81
7.5 Contact Us 82
7.6 Disclaimer 82
List of Tables
Table 1: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical
Approvals, the US, 2012 12
Table 2: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceuticals
Approved, the US, 2011 15
Table 3: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceuticals
Approved, the US, 2010 16
Table 4: Biopharmaceutical Manufacturing in India, China and South Korea, Geographical
Distribution of Cell Culture Capacity (000’ liters), 2011-2017 18
Table 5: Biopharmaceutical Manufacturing in India, China and South Korea, Volume Requirement
for Different Biopharmaceuticals, (000’ liters), 2011-2017 19
Table 6: Biopharmaceutical Manufacturing, Product Demand Distribution in Monoclonal Antibodies
(%), Global, 2011 20
Table 7: Biopharmaceutical Manufacturing, Global Sales of Leading Biologics and Year of Patent
Expiry in the US and Europe 21
Table 8: Biopharmaceutical Manufacturing, Comparative Cost Analysis Between In-House
Biopharmaceutical Production Versus CMOs, Global, 2011 23
Table 9: Biopharmaceutical Manufacturing in India, China and South Korea, Contract
Manufacturing and the Drug Discovery and Research Market, Global, 2007-2016 24
Table 10: Biopharmaceutical Manufacturing, Labor Cost Analysis Comparison ($), the US, Europe,
India, China, 2011 27
Table 11: Biopharmaceutical Manufacturing in India, China and South Korea, Investment Range
6. for Manufacturing Plant Locations, Unit Cost per m3 ($), per m3 Reactor Volume, 2011 28
Table 12: Biopharmaceutical Manufacturing in India, China and South Korea, Average Cost for
Product Development Activity, ($’000) 31
Table 13: Biopharmaceutical Manufacturing in India, China and South Korea, Major Products
Manufactured in India, with Segmentation, 2011 45
Table 14: Biopharmaceutical Manufacturing in India, China and South Korea, Market for Vaccines
in India ($m), 2011-2016 46
Table 15: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical
Market in India ($bn), 2008-2016 47
Table 16: Biopharmaceutical Manufacturing in India, China and South Korea, Pharmaceutical and
Biopharmaceutical Market ($bn), China, 2011-2015 58
Table 17: Biopharmaceutical Manufacturing in India, China and South Korea, Different Categories
of Biopharmaceuticals, Expression System and Indications, China, 2011 59
Table 18: Biopharmaceutical Manufacturing in India, China and South Korea, Innovative
Biopharmaceutical Products, Indications, KFDA Approval Year and Company, 1999-2011 69
Table 19: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical
Market, South Korea ($bn), 2011-2016 70
Table 20: Biopharmaceutical Manufacturing in India, China and South Korea, Major R&D
Achievements in South Korea 72
List of Figures
Figure 1: Biopharmaceutical Manufacturing, Number of FDA Approved Biopharmaceuticals, the
US, 1982-2011 13
Figure 2: Biopharmaceutical Manufacturing, Percentage Share of Biopharmaceuticals in the
Global Pharmaceutical Market, 2001-2011 14
Figure 3: Biopharmaceutical Manufacturing, Global, Production Capacity by Company (%), 2011
17
Figure 4: Biopharmaceutical Manufacturing in India, China and South Korea, Geographical
Distribution of Cell Culture Capacity (000’ liters), 2011-2017 18
Figure 5: Biopharmaceutical Manufacturing in India, China and South Korea, Volume Requirement
for Different Biopharmaceuticals, (000’ liters), 2011-2017 19
Figure 6: Biopharmaceutical Manufacturing, Product Demand Distribution in Monoclonal
Antibodies (%), Global, 2011 20
Figure 7: Biopharmaceutical Manufacturing, Biopharmaceutical Manufacturing Process, Global,
2012 22
Figure 8: Biopharmaceutical Manufacturing, Contract Manufacturing and the Drug Discovery and
Research Market, Global, 2007-2016 24
Figure 9: Biopharmaceutical Manufacturing, Percentage of Outsourcing Non-Core Activities,
Global, 2011 25
Figure 10: Biopharmaceutical Manufacturing in India, China and South Korea, Factors Driving
Growth of CRAMS, 2012 26
Figure 11: Biopharmaceutical Manufacturing in India, China and South Korea, Roche Case Study,
2011 28
7. Figure 12: Biopharmaceutical Manufacturing, Formula for Standard Operating Cost, Global, 2011
29
Figure 13: Biopharmaceutical Manufacturing, Best and Most Likely Case Estimate Scenarios,
Labor Cost ($’000), India and China, 2011-2046 30
Figure 14: Biopharmaceutical Manufacturing in India, China and South Korea, Timeframes in
Months for Various Activities Involved in the Chemistry, Manufacturing and Control Tasks for
Monoclonal Antibody Product Development, 2011 32
Figure 15: Biopharmaceutical Manufacturing in India, China and South Korea, Timeframes in
Months for Various Activities Involved in the Chemistry, Manufacturing and Control Tasks for
Monoclonal Antibody Product Development, 2011 (Continued) 33
Figure 16: Biopharmaceutical Manufacturing in India, China and South Korea, Comparative
Analysis of Used Equipment Versus New Equipment, Global, 2011 35
Figure 17: Biopharmaceutical Manufacturing, Pharmaceutical Deal Value ($bn) and Number of
Deal, Global, 2005-2012 36
Figure 18: Biopharmaceutical Manufacturing, Market Shares of the Pharmaceutical Companies,
Contract Manufacturers and Equity Players (%), Global, 2007-2011 37
Figure 19: Biopharmaceutical Manufacturing, Perfect Partner Relationship, Global, 2011 41
Figure 20: Biopharmaceutical Manufacturing in India, China and South Korea, Comparative
Analysis with Reference to Government Initiatives, Investments and Skills, 2011 43
Figure 21: Biopharmaceutical Manufacturing in India, China and South Korea, Market for Vaccines
in India ($m), 2011-2016 46
Figure 22: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical
Market in India ($bn), 2008-2016 47
Figure 23: Biopharmaceutical Manufacturing in India, China and South Korea, Drivers and Barriers
for Biopharmaceutical Manufacturing, India, 2011 48
Figure 24: Biopharmaceutical Manufacturing in India, China and South Korea, Major
Pharmaceutical Manufacturing Clusters in India, 2011 49
Figure 25: Biopharmaceutical Manufacturing in India, China and South Korea, Regulatory
Framework for Recombinant Drugs, India, 2011 50
Figure 26: Biopharmaceutical Manufacturing in India, China and South Korea, Biocon, Company
Overview, 2011 51
Figure 27: Biopharmaceutical Manufacturing in India, China and South Korea, Serum Institute of
India, Company Overview, 2011 52
Figure 28: Biopharmaceutical Manufacturing in India, China and South Korea, Panacea Biotec,
Company Overview, 2011 53
Figure 29: Biopharmaceutical Manufacturing in India, China and South Korea, Dr. Reddy’s,
Company Overview, 2011 54
Figure 30: Biopharmaceutical Manufacturing in India, China and South Korea, Cipla, Company
Overview, 2011 55
Figure 31: Biopharmaceutical Manufacturing in India, China and South Korea, Lupin, Company
Overview, 2011 56
Figure 32: Biopharmaceutical Manufacturing in India, China and South Korea, Pharmaceutical and
8. Biopharmaceutical Market ($bn),China, 2011-2015 58
Figure 33: Biopharmaceutical Manufacturing in India, China and South Korea, Contract
Manufacturing Market, China ($bn), 2011-2015 63
Figure 34: Biopharmaceutical Manufacturing in India, China and South Korea, Hualan Biological
Engineering Company Overview, 2011 64
Figure 35: Biopharmaceutical Manufacturing in India, China and South Korea, Shanghai Kehua
Biological Engineering Co. Ltd, Company Overview, 2011 65
Figure 36: Biopharmaceutical Manufacturing in India, China and South Korea, Beijing Tiantan
Biological Products Co. Ltd, Company Overview, 2011 66
Figure 37: Biopharmaceutical Manufacturing in India, China and South Korea, Beijing SL
Pharmaceutical Co., Ltd, Company Overview, 2011 67
Figure 38: Biopharmaceutical Manufacturing in India, China and South Korea, Shanghai RAAS
Blood Products Co., Ltd, Company Overview, 2011 68
Figure 39: Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical
Market, South Korea ($bn), 2011-2016 70
Figure 40: Biopharmaceutical Manufacturing in India, China and South Korea, Evolution of
Biopharmaceuticals, South Korea 71
Figure 41: Biopharmaceutical Manufacturing in India, China and South Korea, Celltrion, Company
Overview, 2011 73
Figure 42: Biopharmaceutical Manufacturing in India, China and South Korea, LG Life Sciences,
Company Overview, 2011 74
Figure 43: Biopharmaceutical Manufacturing in India, China and South Korea, Hanwha Chemical,
Company Overview, 2011 75
Figure 44: Biopharmaceutical Manufacturing in India, China and South Korea, ISU Abxis,
Company Overview, 2011 76
Figure 45: Biopharmaceutical Manufacturing in India, China and South Korea, Green Cross,
Company Overview, 2011 77
Contact: sales@reportsandreports.com for more information.